In the latest trading session, 0.72 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.49. With the company’s most recent per share price at $1.03 changed hands at -$0.04 or -3.27% at last look, the market valuation stands at $215.95M. SGMO’s current price is a discount, trading about -208.74% off its 52-week high of $3.18. The share price had its 52-week low at $0.30, which suggests the last value was 70.87% up since then.
Analysts gave the Sangamo Therapeutics Inc (SGMO) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Sangamo Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in red as seen in intraday trades today. With action -11.54%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 1.47%, with the 5-day performance at -11.54% in the red. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -13.03% down.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 58.8% from its recent market value. According to analyst projections, SGMO’s forecast low is 2 with 3 as the target high. To hit the forecast high, the stock’s price needs a -191.26% plunge from its current level, while the stock would need to soar -94.17% for it to hit the projected low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Year-over-year growth is forecast to reach -64.64% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 11.7M. 3 analysts are of the opinion that Sangamo Therapeutics Inc’s revenue for the current quarter will be 30.67M. The company’s revenue for the corresponding quarters a year ago was 2.04M and 481k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 472.97%. The estimates for the next quarter sales put growth at 6,275.61%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.96%. The 2025 estimates are for Sangamo Therapeutics Inc earnings to increase by 68.13%, but the outlook for the next 5-year period is at 39.84% per year.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.894% or 14.06 million shares worth $5.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. With 5.79 shares estimated at $6.0 million under it, the former controlled 2.78% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.71% of the shares, roughly 5.65 shares worth around $5.84 million.
